Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Amylyx Pharmaceuticals In...

    NASDAQ: AMLX · Real-Time Price · USD
    5.43
    -0.09 (-1.63%)
    At close: Jun 16, 2025, 3:59 PM
    5.55
    2.18%
    After-hours: Jun 16, 2025, 06:32 PM EDT

    Amylyx Pharmaceuticals Statistics

    Share Statistics

    Amylyx Pharmaceuticals has 89.14M shares outstanding. The number of shares has increased by 30.29% in one year.

    Shares Outstanding

    n/a
    		 89.14M

    Shares Change (YoY)

    n/a
    		 30.29%

    Shares Change (QoQ)

    n/a
    		 29.26%

    Owned by Institutions (%)

    n/a
    		 73.12%

    Shares Floating

    n/a
    		 65.31M

    Failed to Deliver (FTD) Shares

    n/a
    		 19

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 4.13M, so 4.64% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 4.13M

    Short % of Shares Out

    n/a
    		 4.64%

    Short % of Float

    n/a
    		 5.12%

    Short Ratio (days to cover)

    n/a
    		 4.01

    Valuation Ratios

    The PE ratio is -0.85 and the forward PE ratio is -4.12. Amylyx Pharmaceuticals's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.85

    Forward PE

    n/a
    		 -4.12

    PS Ratio

    n/a
    		 2.95

    Forward PS

    n/a
    		 3.1

    PB Ratio

    n/a
    		 1.56

    P/FCF Ratio

    n/a
    		 -1.53

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Amylyx Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.67, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 6.67

    Quick Ratio

    n/a
    		 6.67

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $710,333.33

    Profits Per Employee

    n/a
    		 $-2,453,195.12

    Employee Count

    n/a
    		 123

    Asset Turnover

    n/a
    		 0.45

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -393K

    Effective Tax Rate

    n/a
    		 0.13%

    Stock Price Statistics

    The stock price has increased by 229.09% in the last 52 weeks. The beta is -0.59, so Amylyx Pharmaceuticals's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.59

    52-Week Price Change

    n/a
    		 229.09%

    50-Day Moving Average

    n/a
    		 4.77

    200-Day Moving Average

    n/a
    		 4.12

    Relative Strength Index (RSI)

    n/a
    		 57.16

    Average Volume (20 Days)

    n/a
    		 901,561

    Income Statement

    In the last 12 months, Amylyx Pharmaceuticals had revenue of 87.37M and earned -301.74M in profits. Earnings per share was -4.43.

    Revenue

    n/a
    		 87.37M

    Gross Profit

    n/a
    		 -37.26M

    Operating Income

    n/a
    		 -314.73M

    Net Income

    n/a
    		 -301.74M

    EBITDA

    n/a
    		 -301.23M

    EBIT

    n/a
    		 -291.88M

    Earnings Per Share (EPS)

    n/a
    		 -4.43
    Full Income Statement

    Balance Sheet

    The company has 77.39M in cash and 1.98M in debt, giving a net cash position of 75.41M.

    Cash & Cash Equivalents

    n/a
    		 77.39M

    Total Debt

    n/a
    		 1.98M

    Net Cash

    n/a
    		 75.41M

    Retained Earnings

    n/a
    		 -606.69M

    Total Assets

    n/a
    		 219.68M

    Working Capital

    n/a
    		 198.21M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -167.65M and capital expenditures -157K, giving a free cash flow of -167.8M.

    Operating Cash Flow

    n/a
    		 -167.65M

    Capital Expenditures

    n/a
    		 -157K

    Free Cash Flow

    n/a
    		 -167.8M

    FCF Per Share

    n/a
    		 -2.46
    Full Cash Flow Statement

    Margins

    Gross margin is -42.65%, with operating and profit margins of -360.22% and -345.36%.

    Gross Margin

    n/a
    		 -42.65%

    Operating Margin

    n/a
    		 -360.22%

    Pretax Margin

    n/a
    		 -345.81%

    Profit Margin

    n/a
    		 -345.36%

    EBITDA Margin

    n/a
    		 -344.77%

    EBIT Margin

    n/a
    		 -360.22%

    FCF Margin

    n/a
    		 -192.06%

    Dividends & Yields

    AMLX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for AMLX is $10.5, which is 93.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $10.5

    Price Target Difference

    n/a
    		 93.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 8.44

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist